.jpg "Dilara Jappar, PhD photo")
Clinical Pharmacology Lead
Boehringer Ingelheim Pharmaceuticals Inc.
Dilara Jappar is a clinical pharmacology lead and Therapeutic Area Head of Clinical Pharmacology in Inflammation in Boehringer Ingelheim Pharmaceuticals. Since she joined Boehringer Ingelheim in 2021, she has supported the clinical drug research and development process by strategic planning of Clinical Pharmacology data generation and by developing and implementing Clinical Pharmacology strategies for both small molecules and biologics. Prior to joining Boehringer Ingelheim, she was a clinical pharmacology reviewer at the FDA in Office of Clinical Pharmacology, Division of Immune and Inflammation Pharmacology where she reviewed numerous New Drug Applications (NDA), including New Molecular Entities (NMEs), and Investigational New Drugs (IND) applications for small molecules and biological products over 11 years from a clinical pharmacology perspective.